News Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Market Closed - OTC Markets Other stock markets 17:02:30 26/06/2024 BST			5-day change	1st Jan Change
6.5 ^USD	0.00%		0.00%	+333.33%

06-28	European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	MT
06-28	Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	06-28	MT
Chardan Raises Price Target on Silence Therapeutics to $55 From $42, Maintains Buy Rating	06-28	MT
Morgan Stanley Raises Price Target on Silence Therapeutics to $49 From $45, Keeps Overweight Rating	06-28	MT
Sector Update: Health Care Stocks Decline in Afternoon Trading	06-27	MT
European Equities Close Mostly Lower Thursday; Bank of England Warns of 'Sharp Correction' Risk	06-27	MT
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading	06-27	MT
Silence Therapeutics Says Divesiran Shows Sustained Hematocrit Reduction in Blood Cancer Study	06-27	MT
Transcript : Silence Therapeutics plc - Special Call	06-27
Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	06-27	BU
Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients	06-27	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	06-26	MT
Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration	06-24	BU
European Equities Traded in the US as American Depositary Receipts Trend Lower Friday But End Week Higher	06-21	MT
Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)	06-20	BU
Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)	06-20	CI
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	06-17	MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading	06-12	MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	05-30	MT
Silence Therapeutics to Present at Jefferies Global Healthcare Conference	05-30	BU
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Tuesday Trading	05-28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Silence Therapeutics plc OTC Markets

Equities

SLNCF

GB00B9GTXM62

Summary

Filters